{"url_path":"/sec/rkto/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 EXHIBITS","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1711786/0001213900-26-057726-index.html","accession_number":"0001213900-26-057726","cik":"0001711786","ticker":"RKTO","issuer_name":"Rocket One Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1711786/0001213900-26-057726-index.html","primary_entity_key":"0001711786","primary_entity_name":"Hoth Therapeutics, Inc."},"word_count":264,"has_tables":true,"body_markdown":"ITEM 6. EXHIBITS\n\n \n\nExhibit No.\n \nDescription\n\n31.1*\n \n[Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002](ea028884001ex31-1.htm)\n\n31.2*\n \n[Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002](ea028884001ex31-2.htm)\n\n32.1**\n \n[Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002](ea028884001ex32-1.htm)\n\n32.2**\n \n[Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002](ea028884001ex32-2.htm)\n\n101.INS*\n \nInline XBRL Instance Document\n\n101.SCH*\n \nInline XBRL Taxonomy Extension Schema Document\n\n101.CAL*\n \nInline XBRL Taxonomy Extension Calculation Linkbase Document\n\n101.DEF*\n \nInline XBRL Taxonomy Extension Definition Linkbase Document\n\n101.LAB*\n \nInline XBRL Taxonomy Extension Label Linkbase Document\n\n101.PRE*\n \nInline XBRL Taxonomy Extension Presentation Linkbase Document\n\n104*\n \nCover Page Interactive Data File - the cover page from the Registrant’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 is formatted in Inline XBRL\n\n \n\n*\nFiled herewith.\n\n \n\n**\nFurnished herewith.\n\n \n\n29\n\n \n\n \n\nSIGNATURES\n\n \n\nPursuant to the requirements of the Securities\nExchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.\n\n \n\n \nHOTH THERAPEUTICS, INC.\n\n \n \n\nDate: May 15, 2026\nBy: \n/s/ Robb Knie\n\n \n \nRobb Knie,\n\n \n \nChief Executive Officer\n\n \n \n(Principal Executive Officer)\n\n \n \n \n\nDate: May 15, 2026\nBy:\n/s/ David Briones\n\n \n \nDavid Briones,\n\n \n \nChief Financial Officer\n\n \n \n(Principal Financial and Accounting Officer)\n\n \n\n30"}